Drug profile · INN
galsulfase
NAGLAZYME
galsulfase (NAGLAZYME) is a dermatan sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — galsulfase
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- INJECTION
- Patents
- 20
- Programs
- 2
- Data quality
- 0.89
Quick answer
galsulfase (NAGLAZYME) is a dermatan sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dermatan sulfate hydrolytic enzyme
Primary target: Dermatan sulfate
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted -
US 12214015
Use of c-type natriuretic peptide variants to treat osteoarthritis
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12076372
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted -
US 12076333
Lysophosphatidylcholine compositions
granted -
US 12023359
Phospholipid compositions for delivery of therapeutic compounds
granted -
US 11918633
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
granted -
US 11865143
Bioeffective krill oil compositions
granted -
US 11819509
Lipid compositions
granted -
US 11739345
Methods of treating phenylketonuria
granted -
US 11505790
Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
granted -
US 11202819
Use of C-type natriuretic peptide variants to treat osteoarthritis
granted -
US 11135251
Methods for improving fillet quality in farmed fish
granted -
US 11065267
Lysophosphatidylcholine compositions
granted -
US 11040088
Delivery of therapeutic compounds to the brain and other tissues
granted -
US 11034956
Oligonucleotide comprising an inosine for treating DMD
granted -
US 11020438
Phospholipid compositions and their preparation
granted -
US 10898525
Krill oil preparations and their uses
granted -
US 10864223
Lipid compositions
granted -
US 10806742
Liquid phospholipid-containing compositions for the preparation of pharmaceuticals
granted
Frequently asked questions
What is galsulfase?
galsulfase (NAGLAZYME) is a dermatan sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for galsulfase?
NAGLAZYME is a marketed brand name for galsulfase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of galsulfase?
galsulfase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.